Independent
Tenure on this board
5.1 yrs
Also a director at
Guardant Health Inc (GH)Olema Pharmaceuticals Inc (OLMA)Biomarin Pharmaceutical Inc (BMRN)Takeda Pharmaceutical Co Ltd (TAK)
Meeting calendar
KYTX · Annual meeting · Wednesday, May 27, 2026
Kyverna Therapeutics Inc
2 nominees · 2 ballot items.
Two management proposals: (1) election of two Class II directors (Ian Clark and Christi Shaw) for three-year terms expiring in 2029; and (2) ratification of the Audit Committee’s appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for the year ending December 31, 2026.
Market cap
$369M
1Y TSR
-3.5%
Board grade
C
Record date
Mar 30, 2026
Filing
DEF 14A
Meeting concluded · May 27, 2026
Follow how the vote landed and what changed on Kyverna Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect two Class II directors (Ian Clark and Christi Shaw) to hold office until the 2029 annual meeting of stockholders.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm and Independent Auditor
ManagementBoard: FORRatify the Audit Committee’s appointment of BDO USA, P.C. as the company’s independent registered public accounting firm and independent auditor for the year ending December 31, 2026.
Director elections
Nominees on the ballot2
Not independent
Tenure on this board
2.1 yrs
Also a director at
Beam Therapeutics Inc (BEAM)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 6.9% | 4,244,818 | $38M |
| 2 | GILEAD SCIENCES, INC. | 6.7% | 4,126,119 | $37M |
| 3 | Bain Capital Life Sciences Investors, LLC | 4.7% | 2,885,000 | $26M |
| 4 | AIGH Capital Management LLC | 3.4% | 2,071,894 | $18M |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.2% | 2,000,000 | $18M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,897,451 | $17M |
| 7 | BlackRock, Inc. | 3.0% | 1,872,122 | $17M |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 1,088,907 | $10M |
| 9 | Insight Holdings Group, LLC | 1.6% | 989,054 | $9M |
| 10 | STATE STREET CORP | 1.6% | 982,233 | $9M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Kyverna Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Galectin Therapeutics IncGALT
Annual meeting·Dec 3, 2026·$374M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$474M
Entera Bio LtdENTX
Special meeting·Nov 24, 2026·$480M
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$487M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$591M
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$629M
Reference
Frequently asked questions
- When is the Kyverna Therapeutics Inc 2026 annual meeting?
- Kyverna Therapeutics Inc (KYTX) holds its 2026 annual shareholder meeting on Wednesday, May 27, 2026.
- What is the record date for the Kyverna Therapeutics Inc 2026 meeting?
- The record date for the Kyverna Therapeutics Inc 2026 meeting is Monday, March 30, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Kyverna Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Kyverna Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Kyverna Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Kyverna Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.